The MarketWatch News Department was not involved in the creation of this content. -- VYVGART(R) SC is first and only neonatal Fc receptor blocker approved to treat CIDP -- Authorization is based on ...
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare but treatable condition. Although the symptoms — muscle weakness, numbness, tingling, and loss of coordination — can significantly ...
Sanofi ((SNYNF)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help ...
Rituximab, a monoclonal antibody that targets the CD20 antigen on B-lymphocytes, may offer therapeutic value in lupus nephritis unresponsive to standard regimens. In patients with relapsed or ...
Argenx (NASDAQ:ARGX) is one of the best biotech stocks to invest in now. On June 20, Argenx announced that the European Commission/EC approved VYVGART (efgartigimod alfa) 1000mg for subcutaneous/SC ...
Argenx (NASDAQ:ARGX) is one of the best biotech stocks to invest in now. On June 20, Argenx announced that the European Commission/EC approved VYVGART (efgartigimod alfa) 1000mg for subcutaneous/SC ...
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that ...
SC injection of VYVGART® is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional SAN DIEGO, June 20, 2025 /PRNewswire/ -- Halozyme ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback